{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=7&q=CAR-T", "query": { "intervention": "CAR-T", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 822, "total_pages": 83, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=8&q=CAR-T&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=6&q=CAR-T&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T08:12:15.408Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04923893", "title": "A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 743, "start_date": "2021-08-19", "completion_date": "2036-09-22", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 19, "location_summary": "San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04923893" }, { "nct_id": "NCT05347485", "title": "A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2022-05-13", "completion_date": "2023-12-15", "has_results": true, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 18, "location_summary": "Duarte, California • San Francisco, California • Stanford, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05347485" }, { "nct_id": "NCT07727668", "title": "Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Multiple Myeloma", "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Iberdomide", "type": "DRUG" }, { "name": "CAR-T Leukapheresis", "type": "PROCEDURE" }, { "name": "CAR-T Infusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Shambavi Richard", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2026-07", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07727668" }, { "nct_id": "NCT05984199", "title": "Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "VCAR33", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vor Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2023-12-11", "completion_date": "2025-05-28", "has_results": false, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 14, "location_summary": "La Jolla, California • Stanford, California • Miami, Florida + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05984199" }, { "nct_id": "NCT06680752", "title": "Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia, in Relapse", "Acute Myeloid Leukemia Refractory", "MDS (Myelodysplastic Syndrome)" ], "interventions": [ { "name": "ARD103", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "ARCE Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2025-05-20", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 3, "location_summary": "Charlotte, North Carolina • Winston-Salem, North Carolina • Houston, Texas", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06680752" }, { "nct_id": "NCT07221032", "title": "FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapse Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "FT836 CAR T cells (1 x 10^8 cells per dose)", "type": "BIOLOGICAL" }, { "name": "FT836 CAR T cells (3 x 108 cells per dose)", "type": "BIOLOGICAL" }, { "name": "FT836 CAR T cells (up to 9 x 108 cells per dose)", "type": "BIOLOGICAL" }, { "name": "Daratumumab 16 mg/kg", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 12, "start_date": "2026-10", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221032" }, { "nct_id": "NCT05618925", "title": "Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin's Lymphoma Refractory/Relapsed" ], "interventions": [ { "name": "N803", "type": "DRUG" }, { "name": "CD19t-haNK suspension", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-08-22", "completion_date": "2027-03-15", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 2, "location_summary": "Newport Beach, California • Tyler, Texas", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05618925" }, { "nct_id": "NCT05826535", "title": "Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Large B-cell Lymphoma" ], "interventions": [ { "name": "Rondecabtagene autoleucel (ronde-cel)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2023-05-09", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 32, "location_summary": "Irvine, California • Los Angeles, California • San Diego, California + 27 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05826535" }, { "nct_id": "NCT05105152", "title": "PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Refractory", "Acute Myeloid Leukemia, in Relapse" ], "interventions": [ { "name": "SC-DARIC33", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 18, "start_date": "2021-11-29", "completion_date": "2041-01-31", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05105152" }, { "nct_id": "NCT06297226", "title": "Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Arlocabtagene Autoleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2024-03-21", "completion_date": "2032-06-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-07T08:12:15.408Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06297226" } ] }